SBFMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFMW
Sunshine Biopharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.24+0.02 (+9.02%)
Close on Oct 19, 2026
- Market cap
- $330.14K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
33.8%−30.0 pts over 5 years
Operating margin
-17.2%+790.7 pts over 5 years
Net margin
-16.5%+3882.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.1% | +102.9% | +247.7% | +170.9% | |
| Gross profit | +14.9% | +93.3% | +206.2% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 866.9% | 329.4% | -25.7% | |
| Return on assets | -948.0% | -486.9% | -19.7% | |
| Current ratio | 0.21 | 0.98 | 4.17 | |
| Debt to equity | 0.00 | -0.99 | – | |
| Net debt to EBITDA | 0.06× | 0.07× | – | |
| Interest coverage | -28.6× | -3.4× | – | |
| Inventory turnover | – | 1.3× | 1.9× | |
| Capex to revenue | – | 1.7% | 0.5% | |
| Diluted shares | 0M | 0M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sunshine Biopharma generated $33.71M from operations and spent $5.79M on capital expenditure, dividends and share buybacks. 36% of that went back into the business.
Generated
$33.71M
Used
$5.79M
Capital expenditure$2.11M36%Dividends$00%Share buybacks$3.68M64%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-16.5%
×Asset turnover1.20×
×Equity multiplier1.30×
=Return on equity, FY2025-25.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -16.5% | 1.20× | 1.30× | -25.7% |
| FY2024 | -14.7% | 1.20× | 1.30× | -23.0% |
| FY2023 | -18.7% | 0.85× | 1.32× | -21.0% |
| FY2022 | -615.4% | 0.28× | 1.44× | -244.9% |
| FY2021 | -5444.4% | 0.14× | -4.37× | 3346.8% |
| FY2020 | -3898.7% | 0.12× | -0.68× | 329.4% |
| FY2019 | -7860.9% | 0.03× | -1.57× | 419.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$5.98M
- Cash generatingOperating cash flow above zero-$5.33M
- Return on assets improvedROA up on the prior year-18.8% → -19.6%
- Earnings backed by cashOperating cash flow above net income-$5.33M vs -$5.98M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.11 → 4.17
- No dilutionShare count did not rise1M → 4M
- Gross margin improvedGross margin up on the prior year30.60% → 33.76%
- More efficientAsset turnover rose1.28 → 1.19